Geographical Distribution of Myasthenia Gravis in Northern Europe--Results from a Population-Based Study from Two Countries.
| Autor: | Boldingh MI; Department of Neurology, Oslo University Hospital, Ullevål and Rikshospitalet, Oslo, Norway., Maniaol AH, Brunborg C, Dekker L, Heldal AT, Lipka AF, Popperud TH, Niks EH, Verschuuren JJ, Tallaksen CM |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Neuroepidemiology [Neuroepidemiology] 2015; Vol. 44 (4), pp. 221-31. Date of Electronic Publication: 2015 Jun 11. |
| DOI: | 10.1159/000431036 |
| Abstrakt: | Objectives: To compare the prevalence of myasthenia gravis (MG) subgroups based on immunological markers and clinical presentation in two geographically complete MG populations in northern Europe. Methods: This cross-sectional study included all living MG patients in Norway and a regional cohort from the Netherlands. Patients were identified using their hospital registration codes. Medical charts of subjects >16 years were reviewed. Inclusion criteria were clinical MG, a positive antibody test for acetylcholine receptor (AChR MG) or muscle-specific kinase (MuSK MG), or if seronegative MG, confirmed by an electrophysiological test. Results: 1,205 MG patients (534 Norwegians and 671 Dutch) fulfilled the criteria, giving a higher point prevalence in the Netherlands (167/million, 95% CI 155-180) than in Norway (138/million, 95% CI 126-150). In particular, rates of AChR MG (143 vs. 111/million), MuSK MG (6.5 vs. 0.5/million), and ocular phenotype (62 vs. 24/million) were higher in the Netherlands. Conclusion: Novel findings are an AChR MG geographical north-south gradient and a 2.6-fold more ocular MG patients in the Netherlands than in Norway. The MuSK MG latitudinal gradient supports the notion of a north-south gradient in Europe, with a higher prevalence in the south. The variation is probably explained by genetic differences between the populations, in addition to environmental interactions. (© 2015 S. Karger AG, Basel.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|